Best Peptides for Fat Loss (Ranked by Evidence)
Most peptide content ranks compounds by popularity or mechanism plausibility. This ranking uses a scoring framework weighted toward what actually matters for predicting real-world fat loss: human clinical trial data first, mechanism clarity second, effect size third, safety profile fourth.
Human trial data
Randomised controlled trials in humans — the gold standard
Mechanism clarity
How well understood is the fat-loss pathway?
Effect size
Magnitude of measurable weight/fat loss in studies
Safety profile
Documented side effects and long-term tolerance
Proven Human Data
Semaglutide (2.4mg)
Human data
5/5
Mechanism
5/5
Effect size
5/5
Safety
4/5
The current benchmark for pharmacological weight loss. SCALE trial: ~15% mean body weight loss. SELECT trial: 20% reduction in cardiovascular events. GLP-1 receptor agonist with the longest clinical track record for obesity.
Tirzepatide (15mg)
Human data
5/5
Mechanism
5/5
Effect size
5/5
Safety
4/5
SURMOUNT-1: 22.5% mean body weight loss — the largest effect size of any weight loss compound in clinical trials. Dual GLP-1 + GIP mechanism. SURMOUNT-5 direct comparison confirmed superiority over semaglutide.
GH-Mediated Lipolysis
CJC-1295 + Ipamorelin Stack
Human data
2/5
Mechanism
4/5
Effect size
3/5
Safety
4/5
GH-mediated lipolysis is real and well-understood. CJC-1295 (GHRH analogue) + Ipamorelin (GHRP) produce synergistic GH pulses that drive fat mobilisation — particularly visceral fat. Limited direct human RCT data for fat loss, but GH's lipolytic effects are documented in GH-deficient populations.
Fat-Targeted GH Fragments
AOD-9604
Human data
2/5
Mechanism
3/5
Effect size
2/5
Safety
3/5
GH fragment 176-191 — theoretically targets fat cells directly via lipolytic pathway without the IGF-1 and insulin effects of full GH. Phase 2 trial data showed modest fat loss. Mechanism is plausible; effect size in humans is unimpressive relative to GLP-1 agents.
Tesamorelin
Human data
4/5
Mechanism
4/5
Effect size
3/5
Safety
4/5
FDA-approved for HIV-associated lipodystrophy — the only GH-axis peptide with approved human fat reduction data. Specifically reduces visceral (abdominal) fat via GHRH receptor activation. Fat-targeted mechanism is well-validated; applicability to general obesity is more limited.
If fat loss is the primary goal and human evidence matters, GLP-1 agonists (semaglutide, tirzepatide) operate in a completely different category from every other compound listed. Their effect sizes in human RCTs — 15–22% body weight loss — are simply not achieved by any other peptide with current human data.
GH secretagogues (CJC-1295, Ipamorelin, Tesamorelin) are real, mechanism-supported tools for improving body composition — primarily through lipolysis and lean mass preservation — but their documented fat loss in human trials is modest compared to GLP-1 agents.
AOD-9604 and peptides with primarily preclinical support are speculative for fat loss purposes at this stage of research.
Research use only. Rankings are based on available published evidence. Research-grade compounds are not pharmaceutical substitutes. Not medical advice.
Weight Loss Peptides Guides
Developed & Edited by Brian Gossett
Created with AI-assisted research and drafting. Sources, conclusions, and final content reviewed by the author.
Founder & Biotechnology Research Industry Entrepreneur
20+ years of entrepreneurial experience • Peptide & biotechnology industry experience
View Staff Profile →Disclosure: Brian is the founder of Base Peptides, a large research peptide supplier. Full disclosure.
Found an error? Review our Corrections Policy or contact us.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →